American Society of Clinical Oncology (ASCO) shared a post on LinkedIn:
“We have published a new Clinical Notice recommending against the use of ivermectin and fenbendazole for cancer treatment outside of clinical trials.
‘ASCO strongly cautions that ivermectin and fenbendazole should not be used for the treatment of cancer, nor as an adjunct to established cancer therapies, outside the regulatory safeguards of a well-designed clinical trial.
The current lack of established clinical benefit, coupled with the potential for toxicity and harmful drug interactions, presents an unacceptable risk to patients.'”
Other articles about ASCO on OncoDaily.